Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxyquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | METAP2 | P50579 | 2/20 | 0.78 |
| ▸ | METAP1 | P53582 | 2/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | COMT | P21964 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1506214-B1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARM INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7129221-B2 | 6,11-bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-7064110-B2 | 6-11 bicycle ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050282758-A1 | 6-11 Bicyclic ketolide derivatives | NIU DEQIANG | 2005-12-22 | — | — | US | disclosed |
| US-20050159370-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1509538-A1 | 6,11 BICYCLIC ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20050037982-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506214-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040157787-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040053861-A1 | 6,11-Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2003097659-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003095466-A1 | 6,11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| EP-1272500-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6437106-B1 | ALKYLATION WITH ALKENYL CARBONATE OR CARBAMATE IN PRESENCE OF PALLADIUM CATALYST AND PHOSPHINE; CYCLIZATION | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| WO-2000078773-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSTITUTED ERYTHROMYCIN DERIV ATIVES | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |